Arrowhead Pharmaceuticals (ARWR) Receivables - Other (2010 - 2025)

Arrowhead Pharmaceuticals' Receivables - Other history runs 12 years deep, the most recent figure standing at $9.8 million for Q4 2025.

• Quarterly Receivables - Other changed N/A year-over-year to $9.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.8 million (changed N/A YoY) and the FY2022 annual result came in at $4.8 million, up 4700.0% from the prior year.
• Receivables - Other was $9.8 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $1.5 million in the prior quarter.
• Across five years, Receivables - Other topped out at $15.0 million in Q4 2022 and bottomed at $100000.0 in Q3 2021.
• A 4-year average of $4.2 million and a median of $1.4 million in 2022 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2021 — Receivables - Other slumped 98.0% — and 2022, when it soared 4700.0%.
• Arrowhead Pharmaceuticals' Receivables - Other stood at $100000.0 in 2021, then jumped by 14900.0% to $15.0 million in 2022, then tumbled by 90.0% to $1.5 million in 2023, then soared by 555.13% to $9.8 million in 2025.
• Business Quant data shows ARWR's Receivables - Other at $9.8 million in Q4 2025, $1.5 million in Q2 2023, and $15.0 million in Q4 2022.